Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension

OBJECTIVE: To evaluate the long-term efficacy and safety of osilodrostat in patients with Cushing’s disease. METHODS: The multicenter, 48-week, Phase III LINC 4 clinical trial had an optional extension period that was initially intended to continue to week 96. Patients could continue in the extensio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadelha, Mônica, Snyder, Peter J., Witek, Przemysław, Bex, Marie, Belaya, Zhanna, Turcu, Adina F., Feelders, Richard A., Heaney, Anthony P., Paul, Michaela, Pedroncelli, Alberto M., Auchus, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482037/
https://www.ncbi.nlm.nih.gov/pubmed/37680892
http://dx.doi.org/10.3389/fendo.2023.1236465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482037/
https://www.ncbi.nlm.nih.gov/pubmed/37680892
http://dx.doi.org/10.3389/fendo.2023.1236465

Ejemplares similares